ClinicalTrials.gg
CompletedNCT03345836Updated Aug 15, 2022Results posted

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

A Phase 3 interventional study of Matching Placebo for Upadacitinib and Upadacitinib in Crohn's Disease, sponsored by AbbVie. Completed at 428 sites in 48 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-15.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
624
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
5th of 27
624 · median 220
Started
2017
with 5 others
Phase 3
16 of 55
1 open now
Registered
32nd of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2017, is one of 16 in phase 3, and was the 32nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Upadacitinib
  • Crohn's Disease
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CD for at least 3 months prior to Baseline.
  • Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score.
  • Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader.
  • Demonstrated an inadequate response or intolerance to any biologic therapy for infliximab, adalimumab, certolizumab pegol, vedolizumab, and ustekinumab.
  • If female, participant must meet the recommendations.

Exclusion criteria

Exclusion Criteria:

  • Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
  • Participant not on stable doses of CD related antibiotics, oral aminosalicylates, or methotrexate (MTX).
  • Participant with the following ongoing known complications of CD: abscess (abdominal or peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, or any other manifestation that might require surgery while enrolled in the study.
  • Participant with ostomy or ileoanal pouch.
  • Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short gut or short bowel syndrome.
  • Screening laboratory and other protocol pre-specified analyses show abnormal results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
624 participants (actual)

Study arms

  • Placebo comparator
    Part 1 (Double-blind): Placebo

    Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.

    Drug: Matching Placebo for Upadacitinib

  • Experimental
    Part 1 (Double-blind): Upadacitinib 45 mg

    Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.

    Drug: Upadacitinib

  • Experimental
    Part 2 (Open-label): Upadacitinib 45 mg

    Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.

    Drug: Upadacitinib

  • Experimental
    Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo

    Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.

    Drug: Upadacitinib

  • Experimental
    Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg

    Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.

    Drug: Upadacitinib

  • Experimental
    Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg

    Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.

    Drug: Upadacitinib

Interventions

  • DrugMatching Placebo for Upadacitinib

    Matching placebo tablets

  • Upadacitinib tablets

    Also known as: ABT-494, RINVOQ®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12

    The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 (NRI-C).

    Time frame: Week 12

  2. Percentage of Participants With Endoscopic Response at Week 12

    Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline of the induction study, at least a 2-point reduction from Baseline), as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.

    Time frame: Baseline to Week 12

  3. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)

Secondary outcomes

  1. Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12

    Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than Baseline. The number of soft or liquid stools and abdominal pain rated on a scale of 0=none to 3=severe were recorded in an electronic diary. Results were based on NRI-C.

    Time frame: Baseline to Week 12

  2. Percentage of Participants With Endoscopic Remission at Week 12

    Endoscopic remission was defined per SES-CD. SES-CD ≤4 and at least 2-point reduction from Baseline and no subscore \>1 in any individual variable, as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.

    Time frame: Baseline to Week 12

  3. Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline

    As prespecified in the protocol, this outcome measure was planned to be assessed in participants taking corticosteroids at Baseline. Clinical remission per CDAI: CDAI \<150. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

    Time frame: Week 12

  4. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 12

    The FACIT-F questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale. The responses to the answers are the following: 0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4=very much. Thus, the total score ranges from 0 to 52. High scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12

    The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The IBDQ scale contains 4 component subscales: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Each item is scored on a 7-point scale where: 1=worst to 7= best. The total score ranges from 32 to 224, with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  6. Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2

    CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 2. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

    Time frame: Baseline to Week 2

  7. Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12

    CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 12. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

    Time frame: Baseline to Week 12

  8. Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 4

    The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

    Time frame: Week 4

  9. Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period)

    Time frame: Up to Week 12 in Part 1: Double-blind Induction Period

  10. Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline

    EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Results were based on NRI-C.

    Time frame: Week 12

07

Results

Posted Aug 15, 2022

Participant flow

Period 1: DB and OL Induction (12 Weeks)
Participant flow — Period 1: DB and OL Induction (12 Weeks)
MilestonePart 1 (Double-blind): PlaceboPart 1 (Double-blind): Upadacitinib 45 mgPart 2 (Open-label): Upadacitinib 45 mgPart 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB PlaceboPart 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mgPart 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg
Started171324129000
Completed149291123000
Not completed22336000
Withdrew: Adverse event5172000
Withdrew: Withdrew consent883000
Withdrew: Lost to follow-up010000
Withdrew: Lack of efficacy840000
Withdrew: Reason not specified131000
Period 2: 12-Week Extended Treatment
Participant flow — Period 2: 12-Week Extended Treatment
MilestonePart 1 (Double-blind): PlaceboPart 1 (Double-blind): Upadacitinib 45 mgPart 2 (Open-label): Upadacitinib 45 mgPart 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB PlaceboPart 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mgPart 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg
Started000786914
Completed00067518
Not completed00011186
Withdrew: Adverse event000850
Withdrew: Withdrew consent000051
Withdrew: Lost to follow-up000001
Withdrew: Lack of efficacy000263
Withdrew: Coronavirus disease (covid-19) logistical restrictions000010
Withdrew: Reason not specified000111

Outcome measures

PrimaryPercentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12

The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 (NRI-C).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 1221.1 (14.9 to 27.2)38.9 (33.6 to 44.2)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated using Cochran-Mantel Haenszel (CMH) test adjusted for randomization stratification factors.) · Adjusted risk difference: 17.9 · 95% CI 10.0 to 25.8Point estimate and 95% confidence interval (CI) were calculated using CMH risk difference estimate.
PrimaryPercentage of Participants With Endoscopic Response at Week 12

Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline of the induction study, at least a 2-point reduction from Baseline), as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 12
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Endoscopic Response at Week 123.5 (0.8 to 6.3)34.6 (29.4 to 39.8)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted risk difference: 31.2 · 95% CI 25.5 to 37.0Point estimate and 95% CI was calculated using CMH risk difference estimate.
PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

Time frame:
From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPart 1 (Double-blind): PlaceboPart 1 (Double-blind): Upadacitinib 45 mgPart 2 (Open-label): Upadacitinib 45 mgPart 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB PlaceboPart 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mgPart 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg
Number of Participants With Adverse Events1122218653459
SecondaryPercentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12

Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than Baseline. The number of soft or liquid stools and abdominal pain rated on a scale of 0=none to 3=severe were recorded in an electronic diary. Results were based on NRI-C.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 1214.0 (8.8 to 19.2)39.8 (34.5 to 45.1)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 25.9 · 95% CI 18.7 to 33.1Point estimate and 95% CI was calculated using CMH.
SecondaryPercentage of Participants With Endoscopic Remission at Week 12

Endoscopic remission was defined per SES-CD. SES-CD ≤4 and at least 2-point reduction from Baseline and no subscore \>1 in any individual variable, as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission at Week 12
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Endoscopic Remission at Week 122.3 (0.1 to 4.6)19.1 (14.9 to 23.4)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 16.8 · 95% CI 12.0 to 21.6Point estimate and 95% CI was calculated using CMH.
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline

As prespecified in the protocol, this outcome measure was planned to be assessed in participants taking corticosteroids at Baseline. Clinical remission per CDAI: CDAI \<150. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline11.7 (3.5 to 19.8)34.3 (25.3 to 43.2)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = 0.0001 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 22.5 · 95% CI 11.1 to 34.0Point estimate and 95% CI was calculated using CMH.
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 12

The FACIT-F questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale. The responses to the answers are the following: 0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4=very much. Thus, the total score ranges from 0 to 52. High scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 12
score on a scalePart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 123.9 ± 0.9711.4 ± 0.69
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · MMRM · p = < 0.0001 (P-value was calculated using mixed effect model repeat measurement (MMRM) with Baseline, treatment, visit, treatment by visit interaction and stratification factors in the model.) · Adjusted treatment difference: 7.5 · 95% CI 5.2 to 9.8Point estimate and 95% CI was calculated using MMRM.
SecondaryChange From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12

The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The IBDQ scale contains 4 component subscales: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Each item is scored on a 7-point scale where: 1=worst to 7= best. The total score ranges from 32 to 224, with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12
score on a scalePart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 1221.6 ± 3.0246.0 ± 2.14
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · MMRM · p = < 0.0001 (P-value was calculated using MMRM with Baseline, treatment, visit, treatment by visit interaction and stratification factors in the model.) · Adjusted treatment difference: 24.3 · 95% CI 17.2 to 31.5Point estimate and 95% CI was calculated using MMRM.
SecondaryPercentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2

CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 2. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Time frame:
Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 212.4 (7.4 to 17.4)33.2 (28.0 to 38.3)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 20.7 · 95% CI 13.7 to 27.8Point estimate and 95% CI was calculated using CMH.
SecondaryPercentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12

CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 12. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 1227.5 (20.8 to 34.2)50.5 (45.1 to 56.0)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 22.8 · 95% CI 14.4 to 31.2Point estimate and 95% CI was calculated using CMH.
SecondaryPercentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 4

The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 4
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 417.7 (11.9 to 23.4)29.6 (24.7 to 34.6)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = 0.0013 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 12.1 · 95% CI 4.7 to 19.5Point estimate and 95% CI was calculated using CMH.
SecondaryPercentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period)
Time frame:
Up to Week 12 in Part 1: Double-blind Induction Period
Reported as:
Number · percentage of participants
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period)
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period)8.8 (4.5 to 13.0)6.2 (3.6 to 8.8)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Chi-squared · p = 0.2834 (P-value was calculated using Chi-squared test.) · Treatment difference: -2.6 · 95% CI -7.6 to 2.4Point estimate and 95% CI was calculated using Chi-squared test.
SecondaryPercentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline

EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Results were based on NRI-C.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline
percentage of participantsPart 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mg
Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline21.7 (11.2 to 32.1)32.8 (24.8 to 40.9)
Statistical analysis
  • Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = 0.0833 (P-value was calculated using CMH test adjusted for randomization stratification factors.) · Adjusted treatment difference: 11.5 · 95% CI -1.5 to 24.4Point estimate and 95% CI was calculated using CMH.

Adverse events

Collected over From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 (Double-blind): Placebo0/171 (0%)17/171 (9.9%)69/171 (40.4%)
Part 1 (Double Blind): Upadacitinib 45 mg1/324 (0.3%)30/324 (9.3%)126/324 (38.9%)
Part 2 (Open Label): Upadacitinib 45 mg0/129 (0%)9/129 (7%)44/129 (34.1%)
Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo0/78 (0%)11/78 (14.1%)29/78 (37.2%)
Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg0/69 (0%)7/69 (10.1%)12/69 (17.4%)
Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg0/14 (0%)5/14 (35.7%)7/14 (50%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventPart 1 (Double-blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mgPart 2 (Open Label): Upadacitinib 45 mgPart 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB PlaceboPart 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mgPart 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg
CROHN'S DISEASEGastrointestinal disorders10/1717/3244/1293/784/693/14
ABDOMINAL ABSCESSInfections and infestations0/1710/3240/1290/780/691/14
GASTROENTERITISInfections and infestations0/1710/3240/1290/780/691/14
HYPOKALAEMIAMetabolism and nutrition disorders0/1710/3240/1290/780/691/14
COVID-19 PNEUMONIAInfections and infestations0/1710/3242/1290/780/690/14
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/1710/3240/1290/781/690/14
LEUKOPENIABlood and lymphatic system disorders0/1710/3240/1290/781/690/14
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/1711/3241/1290/781/690/14
NEPHROLITHIASISRenal and urinary disorders0/1711/3240/1290/781/690/14
ABDOMINAL PAINGastrointestinal disorders0/1711/3240/1291/780/690/14
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPart 1 (Double-blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mgPart 2 (Open Label): Upadacitinib 45 mgPart 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB PlaceboPart 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mgPart 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg
NAUSEAGastrointestinal disorders8/17115/3243/1293/781/692/14
VOMITINGGastrointestinal disorders4/1718/3240/1290/780/692/14
ACNESkin and subcutaneous tissue disorders4/17115/32418/1295/780/690/14
CROHN'S DISEASEGastrointestinal disorders13/17112/3245/1295/784/691/14
INFLUENZAInfections and infestations2/1719/3241/1292/783/691/14
BLOOD PHOSPHORUS DECREASEDInvestigations0/1711/3241/1290/780/691/14
FISTULA DISCHARGEMusculoskeletal and connective tissue disorders0/1710/3240/1290/780/691/14
INSOMNIAPsychiatric disorders2/1715/3241/1291/780/691/14
HAEMATURIARenal and urinary disorders0/1710/3240/1290/780/691/14
ALOPECIASkin and subcutaneous tissue disorders0/1713/3240/1290/780/691/14

Baseline characteristics

Intent-to-Treat (ITT) Population for the 12-week DB Induction Period (Part 1) i.e., ITT1 included all randomized participants who received at least one dose of DB study drug during Part 1. ITT Population for the 12-week OL Induction Period (Part 2) i.e., ITT2 included all participants who received at least one dose of study drug in Part 2.

Age, Continuous
Age, Continuous(years)Part 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mgPart 2 (Open Label): Upadacitinib 45 mgTotal
Part 1 (Double Blind)37.5 (18 to 74)38.4 (18 to 73)—38.1 (18 to 74)
Part 2 (Open Label)——39.1 (18 to 68)39.1 (18 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mgPart 2 (Open Label): Upadacitinib 45 mgTotal
Female7515560290
Male9616969334
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mgPart 2 (Open Label): Upadacitinib 45 mgTotal
Hispanic or Latino824840
Not Hispanic or Latino163300121584
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 (Double Blind): PlaceboPart 1 (Double Blind): Upadacitinib 45 mgPart 2 (Open Label): Upadacitinib 45 mgTotal
American Indian or Alaska Native1102
Asian386911118
Native Hawaiian or Other Pacific Islander0000
Black or African American619530
White126230113469
More than one race0505
Unknown or Not Reported0000
08

Study locations

428 sites
  • East View Medical Research, LLC /ID# 171133
    Mobile, Alabama 36606, United States
  • CB Flock Research Corporation /ID# 166220
    Mobile, Alabama 36608, United States
  • Delsol Research Management, Ll /Id# 170179
    Chandler, Arizona 85224, United States
  • HonorHealth Research Institute - Shea /ID# 164734
    Scottsdale, Arizona 85258, United States
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 203891
    Sun City, Arizona 85306, United States
  • Southern California Res. Ctr. /ID# 169654
    Coronado, California 92118-1408, United States
  • Citrus Valley Gastroenterology /ID# 166201
    Covina, California 91722-3797, United States
  • United Medical Doctors /ID# 207452
    Los Alamitos, California 90720-3309, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 164887
    Los Angeles, California 90067-2001, United States
  • Facey Medical Foundation /ID# 203137
    Mission Hills, California 91345, United States
  • United Medical Doctors - Murrieta /ID# 164845
    Murrieta, California 92563, United States
  • Ucsd /Id# 164679
    San Diego, California 92103, United States
  • Medical Assoc Research Grp /ID# 169705
    San Diego, California 92123, United States
  • UCSF Center for Colitis and Crohn's Disease /ID# 202373
    San Francisco, California 94115-3011, United States
  • Univ of California San Francis /ID# 164843
    San Francisco, California 94158, United States
  • Care Access Research /ID# 167766
    San Pablo, California 94806, United States
  • Peak Gastroenterology Associates, PC /ID# 170181
    Colorado Springs, Colorado 80907, United States
  • Delta Waves, Inc. /ID# 164872
    Colorado Springs, Colorado 80918, United States
  • Duplicate_Western States Clinical Research, Inc. /ID# 164895
    Wheat Ridge, Colorado 80033-2896, United States
  • Medical Research Center of CT /ID# 164829
    Hamden, Connecticut 06518, United States
  • Clinical Research of West Florida, Inc /ID# 205825
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida, Inc /ID# 208117
    Clearwater, Florida 33765, United States
  • Advanced Research - Coral Springs /ID# 218020
    Coral Springs, Florida 33067-3173, United States
  • Encore Borland-Groover Clinical Research /Id# 203498
    Jacksonville, Florida 32256, United States
  • Ctr for Advanced Gastroenterol /ID# 165332
    Maitland, Florida 32751-6108, United States
  • Crystal Pharmacology Research /ID# 166101
    Miami, Florida 33165, United States
  • Coral Research Clinic /ID# 164657
    Miami, Florida 33186-4643, United States
  • Advanced Research Institute, Inc /ID# 164814
    New Port Richey, Florida 34653, United States
  • Endoscopic Research, Inc. /ID# 205893
    Orlando, Florida 32803, United States
  • Omega Research Maitland, LLC /ID# 203480
    Orlando, Florida 32810-2907, United States
  • Clinical Research Trials of Florida, Inc. /ID# 203484
    Tampa, Florida 33607, United States
  • AdventHealth Tampa /ID# 171175
    Tampa, Florida 33613-4680, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 165460
    Macon, Georgia 31201, United States
  • Gastroenterology Consultants PC - Roswell /ID# 218219
    Roswell, Georgia 30076-4913, United States
  • Atlanta Gastroenterology Spec /ID# 164780
    Suwanee, Georgia 30024, United States
  • University of Chicago Medicine /ID# 165472
    Chicago, Illinois 60637-1426, United States
  • DuPage Medical Group /ID# 205303
    Downers Grove, Illinois 60515-5509, United States
  • MediSphere Medical Research Center /ID# 166209
    Evansville, Indiana 47714-8011, United States
  • Indianapolis Gastroenterology /ID# 164837
    Indianapolis, Indiana 46237, United States
  • Aquiant Research /ID# 205504
    New Albany, Indiana 47150-4053, United States
  • University of Iowa Hospitals and Clinics /ID# 165330
    Iowa City, Iowa 52242, United States
  • Tri-State Gastroenterology /ID# 165484
    Crestview Hills, Kentucky 41017, United States
  • University of Louisville /ID# 168536
    Louisville, Kentucky 40202, United States
  • University of Louisville /ID# 208093
    Louisville, Kentucky 40202, United States
  • CroNOLA, LLC /ID# 164722
    Houma, Louisiana 70360, United States
  • Nola Research Works, LLC /ID# 164897
    New Orleans, Louisiana 70115, United States
  • Louisana Research Center, LLC /ID# 164659
    Shreveport, Louisiana 71105-6800, United States
  • Johns Hopkins University School of Medicine /ID# 211940
    Baltimore, Maryland 21287-0010, United States
  • MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 164835
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland /ID# 171171
    Columbia, Maryland 21045, United States
  • Lahey Hospital and Medical Center /ID# 214725
    Burlington, Massachusetts 01805, United States
  • University of Michigan Health Systems /ID# 164844
    Ann Arbor, Michigan 48109, United States
  • Clin Res Inst of Michigan, LLC /ID# 170178
    Chesterfield, Michigan 48047, United States
  • Digestive Health Associates (DHA) - Farmington Hills /ID# 206099
    Farmington Hills, Michigan 48334-3230, United States
  • Center for Digestive Health /ID# 164733
    Troy, Michigan 48098-6363, United States
  • Mayo Clinic - Rochester /ID# 164868
    Rochester, Minnesota 55905-0001, United States
  • Southern Therapy and Advanced Research (STAR) LLC /ID# 165318
    Jackson, Mississippi 39216, United States
  • Quality Clinical Research Inc. /ID# 170177
    Omaha, Nebraska 68114-3723, United States
  • CHI Health Research Center /ID# 168545
    Omaha, Nebraska 68124, United States
  • Las Vegas Medical Research /ID# 168562
    Las Vegas, Nevada 89113, United States
  • AGA Clinical Research Associates, LLC /ID# 164883
    Egg Harbor Township, New Jersey 08234, United States
  • Rutgers Robert Wood Johnson /ID# 166092
    New Brunswick, New Jersey 08901, United States
  • Montefiore Medical Center - Moses Campus /ID# 166226
    Bronx, New York 10467, United States
  • Advantage Clinical Trials /ID# 168557
    Bronx, New York 10468, United States
  • NY Scientific /ID# 164833
    Brooklyn, New York 11235, United States
  • NYU Langone Long Island Clinical Research Associates /ID# 164830
    Lake Success, New York 11042, United States
  • The Mount Sinai Hospital /ID# 170172
    New York, New York 10029, United States
  • Columbia Univ Medical Center /ID# 164870
    New York, New York 10032-3725, United States
  • Gastro Group of Rochester /ID# 166216
    Rochester, New York 14618-5703, United States
  • Richmond University Medical Center /ID# 201855
    Staten Island, New York 10310-1664, United States
  • Atrium Health Carolinas Medical Center /ID# 164834
    Charlotte, North Carolina 28203, United States
  • PMG Research of Charlotte /ID# 171170
    Charlotte, North Carolina 28209, United States
  • Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 164663
    Raleigh, North Carolina 27612, United States
  • Wake Forest Baptist Medical Center /ID# 201225
    Winston-Salem, North Carolina 27157-0001, United States
  • Plains Clinical Research Center, LLC /ID# 170184
    Fargo, North Dakota 58104-5925, United States
  • Consultants for Clinical Research /ID# 164855
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati /ID# 164720
    Cincinnati, Ohio 45267-0585, United States
  • Cleveland Clinic Main Campus /ID# 208220
    Cleveland, Ohio 44195, United States
  • The Ohio State University /ID# 170174
    Columbus, Ohio 43210, United States
  • Optimed Research, Ltd. /ID# 205618
    Columbus, Ohio 43235, United States
  • Hometown Urgent Care and Resea /ID# 201290
    Dayton, Ohio 45424, United States
  • Dayton Gastroenterology, Inc. /ID# 167624
    Englewood, Ohio 45415, United States
  • Great Lakes Medical Research, LLC /ID# 202007
    Mentor, Ohio 44060-6211, United States
  • Digestive Disease Specialists /ID# 201062
    Oklahoma City, Oklahoma 73112, United States
  • Options Health Research, LLC /ID# 164737
    Tulsa, Oklahoma 74104, United States
  • Healthcare Research Consultant /ID# 166228
    Tulsa, Oklahoma 74135, United States
  • University of Pennsylvania /ID# 168402
    Philadelphia, Pennsylvania 19104-5502, United States
  • Thomas Jefferson University /ID# 168014
    Philadelphia, Pennsylvania 19107-4414, United States
  • Pharmacorp Clinical Trials /ID# 164809
    Charleston, South Carolina 29412, United States
  • Gastroenterology Associates, P.A. of Greenville /ID# 164880
    Greenville, South Carolina 29615-3593, United States
  • Rapid City Medical Center - GI Research /ID# 201734
    Rapid City, South Dakota 57701, United States
  • Gastro One /ID# 164718
    Germantown, Tennessee 38138, United States
  • East Tennessee Research Institute /ID# 203612
    Johnson City, Tennessee 37604, United States
  • Quality Medical Research /ID# 205262
    Nashville, Tennessee 37211, United States
  • Vanderbilt University Medical Center /ID# 164846
    Nashville, Tennessee 37232-0011, United States
  • TX Clinical Research Institute /ID# 164848
    Arlington, Texas 76012, United States
  • Inquest Clinical Research /ID# 164865
    Baytown, Texas 77521-2415, United States
  • Texas Digestive Disease Consultants /ID# 209952
    Cedar Park, Texas 78613-5028, United States
  • Texas Digestive Disease Consultants /ID# 209802
    Cedar Park, Texas 78613, United States
  • CliniCore International, LLC /ID# 164662
    Houston, Texas 77027-6812, United States

Showing the first 100 of 428 sites across 48 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Aug 2021, 44 months.

Results were first posted in Aug 2022, 1 year after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 44 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2017
First posted
Nov 17, 2017
StartActual
Nov 29, 2017
Primary completionActual
Aug 11, 2021
CompletionActual
Aug 11, 2021
Results first posted
Aug 15, 2022
Last update
Aug 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03345836
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 29, 2017
Primary completion
Aug 11, 2021
Completion
Aug 11, 2021
Results posted
Aug 15, 2022
Last update
Aug 15, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion